Puma biotechnology, inc. (PBYI)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'12Sep'12Jun'12Mar'12Dec'10
Operating activities:
Net loss

-82,441

-75,595

-95,091

-92,407

-99,317

-113,575

-146,958

-209,937

-243,435

-291,955

-300,538

-289,139

-277,904

-276,011

-265,069

-259,705

-257,802

-239,284

-225,048

-200,475

-174,625

-141,965

0

0

0

-74,352

0

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

7,858

8,077

8,283

8,395

8,178

7,384

6,639

5,484

3,875

2,811

2,035

1,245

1,218

1,149

773

862

804

776

757

717

674

627

0

0

0

265

0

0

0

0

Built-out allowance received from landlord

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

179

0

0

0

-

-

-

-

-464

0

0

0

0

Stock-based compensation

48,096

57,327

64,387

72,981

79,725

86,939

93,865

99,549

104,323

108,735

112,487

115,747

117,518

117,264

109,670

104,876

104,341

94,934

89,626

75,118

54,091

39,151

0

0

0

1,408

0

0

0

0

Disposal of property and equipment

-

-54

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Anti-dilutive warrant

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

18,222

0

0

0

0

Changes in operating assets and liabilities:
Accounts receivable, net

-49,442

8,123

7,432

4,003

64,675

11,103

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory, net

660

545

291

785

-105

596

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,053

0

0

0

-

-

-

-

0

Prepaid expenses and other

1,802

-568

-1,821

-713

-1,435

840

1,610

2,315

2,703

1,142

-1,293

-4,420

-4,099

-3,413

-2,580

187

1,259

958

3,697

3,388

8,308

8,584

0

0

0

707

0

0

0

0

Other current assets

-9,850

-1,464

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-11,648

-1,526

-7,248

-7,115

5,403

-7,008

-1,235

-2,328

-495

7,657

-3,340

-111

-868

2,231

11,095

14,180

12,229

2,806

-8,665

-8,353

-2,584

4,305

0

0

0

-

-

-

-

0

Accrued expenses

-817

22,599

35,254

33,060

35,723

15,783

11,909

18,617

14,798

13,222

12,887

8,230

5,692

2,787

1,173

-1,311

599

-14,805

4,637

6,520

8,418

20,865

0

0

0

-

-

-

-

0

Deferred rent

0

-

-

-

-

-409

-438

-53

-7

99

-154

-623

-4,176

-4,112

-3,832

-3,363

145

-124

-361

-377

-248

-153

0

0

0

-186

0

0

0

0

Post-marketing commitment liability

-

9,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

27,030

22,400

27,847

27,885

-33,982

-24,105

-66,761

-114,406

-142,681

-172,470

-177,822

-157,806

-142,704

-141,690

-133,760

-135,736

-139,473

-154,468

-139,898

-127,353

-110,179

-77,203

0

0

0

-44,012

0

0

0

0

Investing activities:
Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

Purchase of property and equipment

-

-

-

-

-

439

695

544

347

431

843

754

4,367

4,287

3,789

3,876

611

1,002

1,489

1,465

1,321

1,100

0

0

0

591

0

0

0

0

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

159

0

0

0

0

Expenditures for leasehold improvements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

179

261

261

367

192

0

0

0

471

0

0

0

0

Purchase of available-for-sale securities

-

127,198

0

0

0

-

-

-

-

79,729

79,728

98,580

124,754

81,794

84,817

90,813

146,736

214,806

0

0

0

-

-

-

-

-

-

-

-

-

Maturity of available-for-sale securities

96,777

104,532

0

0

0

-

-

-

-

114,724

109,489

113,643

138,777

231,267

252,639

227,605

198,722

133,222

113,288

93,820

114,885

70,277

0

0

0

-

-

-

-

-

Net cash provided by (used in) investing activities

84,123

5,163

8,177

-52,155

-102,166

-57,623

-83,723

-18,287

38,597

-15,436

28,921

14,312

6,660

142,189

161,032

126,819

48,276

-85,863

-103,341

-101,366

-123,901

-63,275

0

0

0

-1,221

0

0

0

0

Financing activities:
Proceeds from issuance of stockholder's convertible note payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

205,133

205,133

205,133

205,196

129,440

0

0

0

-

-

-

-

0

Net proceeds from shares issued under employee stock plans

-

1,351

1,853

2,787

5,587

7,652

19,834

28,555

29,126

26,685

14,227

4,625

1,060

576

1,671

6,916

14,013

28,228

0

0

0

-

-

-

-

-

-

-

-

0

Capital contributions by stockholder

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash provided by financing activities

-

-67,067

-36,574

-35,640

106,386

108,451

139,067

147,788

77,551

75,110

176,081

166,479

162,914

162,430

1,671

6,916

13,950

233,361

238,574

233,200

226,166

135,973

0

0

0

-

-

-

-

0

Net increase (decrease) in cash, cash equivalents and restricted cash

42,940

-39,528

-540

-59,893

-29,762

26,723

-11,417

15,095

-26,533

-112,796

27,180

22,985

26,870

162,929

28,943

-2,001

-77,247

-6,970

-4,665

4,481

-7,914

-4,505

0

0

0

84,026

0

0

0

0

Supplemental disclosures of non-cash investing and financing activities:
Property and equipment purchases in accounts payable

0

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Receivables related to stock option exercises

-

-

-

-

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of cash flow information:
Interest paid

10,786

11,739

12,385

13,524

10,294

8,055

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-